Washington, DC (March 13, 2019) – The Leukemia & Lymphoma Society (LLS) is proud to support the Cancer Drug Parity Act, which will remove a key financial barrier that prevents some patients from accessing their prescribed cancer treatments. This bipartisan legislation was reintroduced today in the U.S. House of Representatives by Representative Brian Higgins (D-N.Y.), Representative Brett Guthrie (R-Ky.), Repre...
Rye Brook, N.Y. (Mar. 1, 2019) — As costs for cancer care skyrocket, The Leukemia & Lymphoma Society® (LLS) is putting forward 31 policy recommendations aimed at lowering the cost of cancer care for patients, while protecting access to quality care. Louis J. DeGennaro, Ph.D., LLS president and CEO, issued the following statement regarding the cost of cancer care: “The hig...
(Rye Brook, NY, Jan. 15 2019) – Groundbreaking advances that harness the body’s immune system to attack cancer cells are set to continue, as well as significant focus on new therapies for children with cancer. And expect the revolution to gain steam in cancer treatments moving away from toxic chemotherapy toward genetics-driven targeted therapies, the foundation of precision medicine. This according to L...
Washington, DC (December 12, 2018) – The Leukemia & Lymphoma Society (LLS) is proud to support the Cancer Drug Parity Act, which will ensure equality of insurance coverage for all cancer treatments, regardless of how these treatments are administered. This bipartisan legislation was introduced today in the U.S. Senate by Senator Tina Smith (D-Minn.), Senator Jerry Moran (R-Kan.), Senator Chris Murphy (D-Conn.) ...
(RYE BROOK, N.Y., Dec. 4, 2018) – Burlington Stores and The Leukemia & Lymphoma Society (LLS) joined forces for the 17th consecutive year to help save lives and bring smiles to those touched by blood cancer. From September 9 through December 1, Burlington's more than 670 locations nationwide encouraged customers to donate $1 or more at checkout to support LLS's goal to create a world without blood cancer. This ...
Have media inquiries? Contact us between 9 a.m. and 5 p.m. ET, Monday through Friday: